ArticlePloS one2025
Screening and validation of 3'-Methoxydaidzein as a therapeutic agent in ulcerative colitis based on disulfidptosis-associated molecular clusters.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Disulfidptosis: Mechanisms, evidence boundaries, and translational opportunities.Redox biology · 2026Review
- Metabolic cell death networks in Alzheimer's disease: mechanistic links and therapeutic perspectives of ferroptosis, cuproptosis, and disulfidptosis.Frontiers in cell and developmental biology · 2026Review
- Gut microbiota-regulated cell death: a review on pyroptosis, ferroptosis, and related mechanisms.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis (UC) is a recurrent inflammatory condition of the bowel with a multifaceted pathogenesis, including programmed cell death, oxidative stress, and immune-mediated inflammation. As a recently identified type of cell death, disulfidptosis has an unclear role in UC.
methodsWe analyzed clusters of disulfidptosis-related genes (DRGs) and immune cell infiltration in 361 patients with UC from the GSE73661and GSE92415 datasets. Differentially expressed genes (DEGs) were identified using unsupervised clustering methods, and hub genes were selected using machine learning algorithms. Additionally, potential key components of potential traditional Chinese medicines for the treatment of UC were predicted based on hub genes. Finally, experimental validation was performed through qRT-PCR, western blotting, and immunohistochemistry.
resultsWe identified two molecular clusters related to disulfidptosis, each showing significant heterogeneity in gene expression and immune profiles. Hub genes associated with disulfidptosis, CXCL1, HMGCS2, AQP8, and SLC26A2, were further screened and validated. Additionally, potential traditional Chinese medicines for UC were predicted. 3'-Methoxydaidzein (MHD), a key constituent of Puerariae Radix, inhibited LPS-induced inflammatory responses in Caco2 cells and alleviated DSS-induced colonic injury in UC mice via upregulation of SLC26A2.
conclusionDRGs demonstrate strong discriminatory power in distinguishing UC subtypes. Cluster with high expression of SLC26A2 showed a UC phenotype with a milder degree of damage. Additionally, we identified the hub gene SLC26A2 as playing a significant role in UC, and MHD demonstrates potential as a targeted therapeutic strategy for UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.